Aller au contenu principal
Retour à l'annuaire
RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

M. Docteur ALDO MORRONE

📍 Dijon (21)Libéral💶 Secteur 2RPPS 10002150331
📊 Reconnaissance scientifique : 36/100📝 315 articles publiés📚 HAL (1)

✨ Profil synthétique

IA · 05/05/2026

Le Dr Aldo Morrone est un rhumatologue libéral à Dijon avec une production scientifique importante, comme en témoignent ses 315 publications et son h-index de 36. Ses recherches couvrent notamment les maladies dermatologiques, le psoriasis, et les études cliniques sur la COVID-19. Il a également des intérêts de recherche dans l'épidémiologie, la pharmacovigilance et l'utilisation de l'intelligence artificielle en rhumatologie.

Expertises présumées

  • Psoriasis
  • Dermatologie
  • Pharmacovigilance
  • Épidémiologie
  • Essais cliniques
  • COVID-19
  • Rhumatologie pédiatrique
  • Thérapeutiques anti-IL-17

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Thèses universitaires

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

36

h articles cités ≥ h fois chacun. Un h de 36 = 36 publications avec 36+ citations.

Citations

5 016

Publications

315

i10-index

119

Thématiques principales

  • SARS-CoV-2 and COVID-19 Research ×29
  • Dermatological diseases and infestations ×22
  • COVID-19 Clinical Research Studies ×20
  • Psoriasis: Treatment and Pathogenesis ×20
  • Dermatology and Skin Diseases ×20
Voir sur OpenAlex ↗🆔 ORCID 0000-0002-6108-8996

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

🟡 Secteur 2 — Honoraires libresSource CNAM (Annuaire santé Ameli)
💳 Carte VitaleLibéral intégral
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Vidéos & interventions (1)

Source YouTube · recherche par nom (homonymes possibles).

Top publications · les plus citées

  • 1
    Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents

    Scientific reports · 2022

    📚 66 citations🎯 RCR 8.01Top 4% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractAcne vulgaris is a common inflammatory disorder affecting more than 80% of young adolescents. Cutibacterium acnes plays a role in the pathogenesis of acne lesions, although the mechanisms are poorly understood. The study aimed to explore the microbiome at different skin sites in adolescent acne and the role of biofilm production in promoting the growth and persistence of C. acnes isolates. Microbiota analysis showed a significantly lower alpha diversity in inflammatory lesions (LA) than in non-inflammatory (NI) lesions of acne patients and healthy subjects (HS). Differences at the species level were driven by the overabundance of C. acnes on LA than NI and HS. The phylotype IA1 was more represented in the skin of acne patients than in HS. Genes involved in lipids transport and metabolism, as well as potential virulence factors associated with host-tissue colonization, were detected in all IA1 strains independently from the site of isolation. Additionally, the IA1 isolates were more efficient in early adhesion and biomass production than other phylotypes showing a significant increase in antibiotic tolerance. Overall, our data indicate that the site-specific dysbiosis in LA and colonization by virulent and highly tolerant C. acnes phylotypes may contribute to acne development in a part of the population, despite the universal carriage of the microorganism. Moreover, new antimicrobial agents, specifically targeting biofilm-forming C. acnes, may represent potential treatments to modulate the skin microbiota in acne.

  • 2
    Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review

    Drug safety · 2021

    📚 57 citations🎯 RCR 3.98Top 11% NIH
  • 3
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

    Clinical cancer research : an official journal of the American Association for Cancer Research · 2021

    📚 46 citations🎯 RCR 1.95🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Purpose: We assessed the immunogenicity and safety of the BNT162b2 vaccine in a large cohort of patients with cancer (CP). Experimental Design: From March 1, 2021 to March 20, 2021, this prospective cohort study included 816 CP afferent to our institution and eligible for the vaccination. A cohort of 274 health care workers (HCW) was used as age- and sex-matched control group. BNT162b2 was administered as a two-dose regimen given 21 days apart. Blood samples to analyze anti-Spike (S) IgG antibodies (Ab) were collected prevaccination [timepoint (TP) 0], and at 3 weeks (TP1) and 7 weeks (TP2) after the first dose. Results: Patients characteristics: median age 62 (range, 21–97); breast/lung cancer/others (31/21/48%); active treatment/follow-up (90/10%). In the whole CP cohort, the serologic response rate (RR) and the titre of anti-S IgG significantly increased across the TPs; at TP2, the responders (IgG >15 AU/mL) were 94.2%. Active chemotherapy and chronic use of steroids were independent predictors of lower RR. Adverse events (AE) after the booster predicted higher likelihood of response (OR, 4.04; 95% confidence interval, 1.63–9.99; P = 0.003). Comparing the matched cohorts, the responders were significantly lower in CP than in HCW at TP1 (61.2% vs. 93.2%) and TP2 (93.3% vs. 100%), while the geometric mean concentration of IgG did not significantly differ at TP2 being significantly lower in CP (23.3) than in HCW (52.1) at TP1. BNT162b2 was well tolerated in CP; severe-grade AEs were 3.5% and 1.3% after the first and second doses, respectively. Conclusions: BNT162b2 assures serologic immunization without clinically significant toxicity in CP. The second dose is needed to reach a satisfactory humoral response.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal39

▼

Pharmacovigilance4

▼

Épidémiologie & registres2

▼

Pédiatrie2

▼

Anti-IL-171

▼

Essai clinique1

▼

IA en rhumatologie1

▼

Qualité de vie / PROMs1

▼

Revue / méta-analyse1

▼

Revue générale1

▼

Vraie vie / RWE1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.